Enroll Now
Enroll Now

Ivermectin and Cancer Research

Research on Ivermectin

Ivermectin and Cancer Treatment: Research Insights

 

Ivermectin, widely known as an antiparasitic drug, has recently gained attention for its potential in cancer treatment. Preclinical studies have shown promising results, indicating that ivermectin may inhibit cancer cell growth by targeting specific pathways, such as the Wnt/β-catenin signaling pathway, which is often dysregulated in cancers like breast, lung, and colorectal cancer. 

Research published in journals like Pharmacological Research suggests ivermectin induces apoptosis (programmed cell death) and suppresses tumor proliferation in various cancer cell lines. Additionally, its ability to modulate the tumor microenvironment and enhance the efficacy of existing chemotherapies has sparked interest in its use as an adjunct therapy. 

Ongoing studies are exploring its synergistic effects with drugs like paclitaxel and its role in overcoming drug resistance in cancers such as leukemia. For patients and healthcare providers seeking alternative cancer therapies, staying informed about ivermectin’s evolving research is crucial. 

 

      • Recombinant Methioninase (rMETase) Synergistically Sensitizes Ivermectin-resistant MCF-7 Breast Cancer Cells 9.9 Fold to Low-dose Ivermectin.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Ivermectin Combined With Recombinant Methioninase (rMETase) Synergistically Eradicates MiaPaCa-2 Pancreatic Cancer Cells.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Pharmacoproteomics reveals energy metabolism pathways as therapeutic targets of ivermectin in ovarian cancer toward 3P medical approaches.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Ivermectin Enhances Paclitaxel Efficacy by Overcoming Resistance Through Modulation of ABCB1 in Non-small Cell Lung Cancer.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Ivermectin inhibits the growth of ESCC by activating the ATF4-mediated endoplasmic reticulum stress-autophagy pathway.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Spatial proteomics of Onchocerca volvulus with pleomorphic neoplasms shows local and systemic dysregulation of protein expression.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Avermectin B1 mediates antitumor activity and induces autophagy in osteosarcoma through the AMPK/ULK1 signaling pathway.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Ivermectin Synergizes with Modulated Electro-hyperthermia and Improves Its Anticancer Effects in a Triple-Negative Breast Cancer Mouse Model.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Silencing of tropomodulin 1 inhibits acute myeloid leukemia cell proliferation and tumor growth by elevating karyopherin alpha 2-mediated autophagy.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Overcoming flumatinib resistance in chronic myeloid leukaemia: Insights into cellular mechanisms and ivermectin’s therapeutic potential.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Importin subunit beta-1 mediates ERK5 nuclear translocation, and its inhibition synergizes with ERK5 kinase inhibitors in reducing cancer cell proliferation.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Computational Modeling to Identify Drugs Targeting Metastatic Castration-Resistant Prostate Cancer Characterized by Heightened Glycolysis.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Drug repurposing-based nanoplatform via modulating autophagy to enhance chemo-phototherapy against colorectal cancer.” (https://pubmed.ncbi.nlm.nih.gov)

      • “68Ga-FAPI-04 PET/CT in Non-Small Cell Lung Cancer: Accurate Evaluation of Lymph Node Metastasis and Correlation with Fibroblast Activation Protein Expression.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Structural and molecular characterization of lopinavir and ivermectin as breast cancer resistance protein (BCRP/ABCG2) inhibitors.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Targeting Heat Shock Protein 27 and Fatty Acid Oxidation Augments Cisplatin Treatment in Cisplatin-Resistant Ovarian Cancer Cell Lines.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Eprinomectin: a derivative of ivermectin suppresses growth and metastatic phenotypes of prostate cancer cells by targeting the β-catenin signaling pathway.” (https://pubmed.ncbi.nlm.nih.gov)

      • “The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Ivermectin Affects Neutrophil-Induced Inflammation through Inhibition of Hydroxylysine but Stimulation of Cathepsin G and Phenylalanine Secretion.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Persistent elevation of lysophosphatidylcholine promotes radiation brain necrosis with microglial recruitment by P2RX4 activation.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Ivermectin-induced cell death of cervical cancer cells in vitro a consequence of precipitate formation in culture media.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Ivermectin accelerates autophagic death of glioma cells by inhibiting glycolysis through blocking GLUT4 mediated JAK/STAT signaling pathway activation.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Molecular Docking and Dynamics Simulation Revealed Ivermectin as Potential Drug against Schistosoma-Associated Bladder Cancer Targeting Protein Signaling: Computational Drug Repositioning Approach.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Androgen receptor (AR) antagonism triggers acute succinate-mediated adaptive responses to reactivate AR signaling.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer.” (https://pubmed.ncbi.nlm.nih.gov)

      • “A Gene Expression Biomarker Identifies Chemical Modulators of Estrogen Receptor α in an MCF-7 Microarray Compendium.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Development of a miRNA-controlled dual-sensing system and its application for targeting miR-21 signaling in tumorigenesis.” (https://pubmed.ncbi.nlm.nih.gov)

      • “SILAC quantitative proteomics analysis of ivermectin-related proteomic profiling and molecular network alterations in human ovarian cancer cells.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Eprinomectin, a novel semi-synthetic macrocylic lactone is cytotoxic to PC3 metastatic prostate cancer cells via inducing apoptosis.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Vincristine and ivermectin combination chemotherapy in dogs with natural transmissible venereal tumor of different cyto-morphological patterns: A prospective outcome evaluation.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 in oesophageal squamous cell carcinoma.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Identification of Functional Transcriptional Binding Sites within Chicken Abcg2 Gene Promoter and Screening Its Regulators.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt/mTOR Signaling.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Anti-parasitic Drug Ivermectin Exhibits Potent Anticancer Activity Against Gemcitabine-resistant Cholangiocarcinoma In Vitro.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Macrocyclic lactones inhibit nasopharyngeal carcinoma cells proliferation through PAK1 inhibition and reduce in vivo tumor growth.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Synchronous MALT lymphoma of the colon and stomach and regression after eradication of Strongyloides stercoralis and Helicobacter pylori.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Antibiotic ivermectin selectively induces apoptosis in chronic myeloid leukemia through inducing mitochondrial dysfunction and oxidative stress.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Demodex-Positive Acneiform Eruption Responsive to Ivermectin in a Patient Taking an Epidermal Growth Factor Inhibitor.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Apoptosis of leukemia K562 and Molt-4 cells induced by emamectin benzoate involving mitochondrial membrane potential loss and intracellular Ca2+ modulation.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Long-Lasting WNT-TCF Response Blocking and Epigenetic Modifying Activities of Withanolide F in Human Cancer Cells.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Autophagosome Proteins LC3A, LC3B and LC3C Have Distinct Subcellular Distribution Kinetics and Expression in Cancer Cell Lines.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Characterization of multidrug transporter-mediated efflux of avermectins in human and mouse neuroblastoma cell lines.” (https://pubmed.ncbi.nlm.nih.gov)

      • “The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Strongyloides stercoralis hyperinfection presenting as subacute small bowel obstruction following immunosuppressive chemotherapy for multiple myeloma.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Hyperinfection by Strongyloides stercoralis probably associated with Rituximab in a patient with mantle cell lymphoma and hyper eosinophilia.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Transmembrane potential of GlyCl-expressing instructor cells induces a neoplastic-like conversion of melanocytes via a serotonergic pathway.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Immunohistological studies on neoplasms of female and male Onchocerca volvulus: filarial origin and absence of Wolbachia from tumor cells.” (https://pubmed.ncbi.nlm.nih.gov)

      • “The direct PAK1 inhibitor, TAT-PAK18, blocks preferentially the growth of human ovarian cancer cell lines in which PAK1 is abnormally activated by autophosphorylation at Thr 423.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Ivermectin inactivates the kinase PAK1 and blocks the PAK1-dependent growth of human ovarian cancer and NF2 tumor cell lines.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Secondary Strongyloides stercoralis prophylaxis in patients with human T-cell lymphotropic virus type 1 infection: report of two cases.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Subcutaneous ivermectin as a safe salvage therapy in Strongyloides stercoralis hyperinfection syndrome: a case report.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Evidence for macrofilaricidal activity of ivermectin against female Onchocerca volvulus: further analysis of a clinical trial in the Republic of Cameroon indicating two distinct killing mechanisms.” (https://pubmed.ncbi.nlm.nih.gov)

      • “Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity.” (https://pubmed.ncbi.nlm.nih.gov)

    Integrative oncologist, Jonathan Stegall, MD, provides a long-awaited and much-needed remedy for our cancer problem. Dr. Stegall has a successful integrative oncology practice in Atlanta, GA, and has seen firsthand what works and what doesn’t when it comes to cancer treatment.

    main menu

    Quick links

    Amazon Books

    Social media links

    Facebook Youtube Amazon Itunes-note
    © 2025 Cancer Secrets University. All rights reserved.
    Skip to content